Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Clinical Disorder Treatment Market size is poised to witness over 6.3% CAGR during the forecast period i.e., between 2025-2037.
The growth of the market can be attributed to the increasing prevalence of psychiatric and psychological disorders, and rising cases of substance abuse among adolescents around the world. According to a statistical report titled Global Burden of Diseases, Injuries, and Risk Factors Study 2017 (GBD 2017), as of 2017, 264 million people were affected by depression, whereas, dementia affected nearly 50 million people globally. Along with these, mounting need for effective management of anxiety and depression related disorders is also expected to drive market growth in the coming years. Furthermore, many hospitals, clinics and health institutions are organizing campaigns to create awareness about relevant treatment options for clinical disorders among general public. This in turn is projected to offer abundant growth opportunities to the clinical disorder treatment market in the near future.
Clinical Disorder Treatment Sector: Growth Drivers and Challenges
Growth Drivers
- Increasing Prevalence of Psychiatric and Psychological Disorders
- Rising Cases of Substance Abuse Among Adolescents Worldwide
Challenges
- Adverse Effects of High Dosage of Treatment Drugs
Clinical Disorder Treatment Market: Key Insights
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
6.3% |
|
Regional Scope |
|
Clinical Disorder Treatment Segmentation
The market is segmented by drug class into antidepressants, anticonvulsants, anxiolytics, atypical antipsychotics, and noradrenergic agents, out of which, the antidepressants segment is anticipated to hold the largest share in the global clinical disorder treatment market. This can be accounted to the high efficacy rate of antidepressants in lowering an individual’s depressive state of mind as compared to other available medications. Apart from these, increasing number of pipeline candidates and product approvals of antidepressants is also predicted to boost the market segment growth in the future. Additionally, on the basis of drug distribution channel, the hospital pharmacy segment is assessed to acquire the largest share during the forecast period owing to the increasing patient visits in hospitals, and high preference of patients to get treatment from hospitals.
Our in-depth analysis of the global market includes the following segments:
|
By Drug Class |
|
|
By Indication |
|
|
By Drug Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportClinical Disorder Treatment Industry - Regional Synopsis
On the basis of geographical analysis, the global clinical disorder treatment market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and the Middle East & Africa region. Asia Pacific industry is predicted to dominate majority revenue share by 2037, ascribed to growing incidences of substance abuse among teenagers and adults, especially in India and China, and increasing prevalence of clinical disorders in the region. In 2019, approximately 30 million people in South Asia admitted to using cannabis. Along with this, 22 million people consumed opioids in the region that year. Moreover, the market in North America is projected to acquire the largest share during the forecast period ascribing to the rising awareness levels about the symptoms of clinical disorders, and high healthcare spending in the region. In addition, strong presence of prominent market players is also expected to propel the clinical disorder treatment market growth in the region in the coming years.
Companies Dominating the Clinical Disorder Treatment Landscape
- Universal Health Services, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- CareTech Holdings PLC
- Behavioral Health Network, Inc.
- Pfizer Inc.
- GlaxoSmithKline plc
- Eli Lilly and Company
- AstraZeneca Plc
- Bristol Myers Squibb Company
- Johnson & Johnson Services, Inc.
- VistaGen Therapeutics, Inc.
In the News
-
May 2021- VistaGen Therapeutics announced the initiation of its PALISADE Phase-3 clinical program to test the efficacy and safety of PH94B for the acute treatment of social anxiety disorder among adults.
-
November 2020- Janssen Pharmaceuticals, a company of Johnson & Johnson, collaborated with Koa Health to research ways for pairing the delivery of digital cognitive behavioral therapy with pharmacological treatments to help patients with major depressive disorder.
Author Credits: Radhika Pawar
- Report ID: 3749
- Published Date: Dec 24, 2024
- Report Format: PDF, PPT
